Stock Ratings | Ascendiant Capital maintained its "buy" recommendation on Outlook Therapeutics (OTLK) but lowered its price target from $10 to $6, still seeing upside potential of 1282.17%.
INmune Bio, Inc. INMB | 0.00 | |
MoonLake Immunotherapeutics Class A MLTX | 0.00 | |
Genasys, Inc. GNSS | 0.00 | |
OCUGEN INC OCGN | 0.00 | |
Outlook Therapeutics, Inc. OTLK | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
LUCID CAPITAL MARKETS: Upgraded INmune Bio ( INmune Bio, Inc.(INMB.US) ) stock rating to "buy" with increased price target from $2 to $9.
Clear Street: Maintaining a "buy" rating on MoonLake Immunotherapeutics Class A ( MoonLake Immunotherapeutics Class A(MLTX.US) ), while raising the price target from $45 to $70.
Ascendiant Capital: Maintaining a "buy" rating on Genasys ( Genasys, Inc.(GNSS.US) ), while raising the price target from $5.25 to $5.5.
Oppenheimer: Initial rating for Ocugen ( OCUGEN INC(OCGN.US) ) stock at "outperforms the market", with a price target of $10.
Ascendiant Capital: Maintaining Outlook Therapeutics ( Outlook Therapeutics, Inc.(OTLK.US) ) rating at "Buy", while lowering the price target from $10 to $6.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| INmune Bio, Inc.(INMB.US) | to lift | $9.0 | $1.42 | 533.8% | LUCID CAPITAL MARKETS |
| MoonLake Immunotherapeutics Class A(MLTX.US) | to lift | $70.0 | $17.84 | 292.38% | Clear Street |
| Genasys, Inc.(GNSS.US) | to lift | $5.5 | $1.86 | 195.7% | Ascendiant Capital |
| Biohaven Ltd.(BHVN.US) | to lift | $30.0 | $10.46 | 186.81% | TD Cowen |
| Cullinan Therapeutics, Inc.(CGEM.US) | to lift | $36.0 | $14.31 | 151.57% | Wedbush |
| OCUGEN INC(OCGN.US) | Initial classification | $10.0 | $2.3 | 334.78% | Oppenheimer |
| Outlook Therapeutics, Inc.(OTLK.US) | cut | $6.0 | $0.4341 | 1282.17% | Ascendiant Capital |
| GRI Bio(GRI.US) | cut | $40.0 | $2.94 | 1260.54% | Ascendiant Capital |
| SharpLink Gaming(SBET.US) | cut | $40.0 | $7.59 | 427.01% | Citizens |
| enGene Holdings(ENGN.US) | cut | $30.0 | $6.88 | 336.05% | Oppenheimer |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Barclays: Maintaining an "overweight" rating on Hims & Hers Health ( Hims & Hers Health, Inc. Class A(HIMS.US) ), while raising the price target from $25 to $29.
Citigroup: Maintaining its "buy" rating on Johnson & Johnson Johnson & Johnson(JNJ.US) ), while raising its price target from $250 to $274.
Barclays: Upgrades Nike ( NIKE, Inc. Class B(NKE.US) ) stock to "overweight", raising its price target from $64 to $73.
JP Morgan: Upgraded Oracle ( Oracle Corporation(ORCL.US) stock to "overweight", while lowering its price target from $230 to $210.
Barclays: Maintaining Oracle's ( Oracle Corporation(ORCL.US) rating at "overweight", while raising the price target from $230 to $240.
First Coverage
Wells Fargo: Hasbro, Inc.(HAS.US) stock has an initial rating of "market-weighted" with a price target of $98.
Wells Fargo: Initial rating for Harley-Davidson ( Harley-Davidson, Inc.(HOG.US) ) at "Underweight", with a price target of $15.
UBS: Initial rating for JOYY ( JOYY Inc(JOYY.US) ) stock at "Buy", with a target price of $80.
Barclays: Nova Measuring Instruments ( Nova Ltd.(NVMI.US) ) initial rating at "overweight", with a price target of $465
Oppenheimer: Initial rating for Ocugen ( OCUGEN INC(OCGN.US) ) stock at "outperforms the market", with a price target of $10.
reduction
Citigroup: Maintaining a "buy" rating on BioNTech BioNTech(BNTX.US) ) stock, while lowering its price target from $145 to $130.
Goldman Sachs: Maintaining a "neutral" rating on Lululemon stock ( lululemon athletica inc.(LULU.US) ), while lowering its price target from $200 to $184.
Piper Sandler: Maintain Oracle's Oracle Corporation(ORCL.US) ) rating at "overweight", while lowering the price target from $240 to $210.
BMO Capital: Maintaining Oracle's Oracle Corporation(ORCL.US) ) rating at "Outperform Market", while lowering the price target from $205 to $200.
Keybanc: Maintaining its "Overweight" rating on Exagen ( Exagen(XGN.US) ), while lowering its price target from $15 to $10
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.